Companies
Regeneron Pharmaceuticals
BiotechnologyTarrytown, New YorkREGN15,410 employees
More about Regeneron Pharmaceuticals
Biotechnology company that discovers, develops and sells medicines for eye disease, allergic and inflammatory conditions and cancer
Revenue
$14.3B
Fiscal 2025, up 1%
Employees
15,410
As of December 2025
Stock
REGN
Nasdaq
Headquarters
Tarrytown, New York
CEO
Leonard S. Schleifer
Also board co-chair
BrandsEylea HD, Eylea, Dupixent (with Sanofi), Libtayo
Current strategyRelying on four blockbuster medicines while advancing its late-stage pipeline and investing in a planned $2 billion manufacturing site in Saratoga Springs, New York
Recent workforce changesPlanned Saratoga Springs, New York manufacturing site announced in early 2026 is expected to create about 1,000 jobs
CompetitorsAmgen, Vertex Pharmaceuticals, Biogen
Related companiesSanofiAmgenVertex Pharmaceuticals
Checked October 11, 2026 · Sources: investor.regeneron.com, regeneron.com
Be the first to post about Regeneron Pharmaceuticals
No one has started a discussion here yet. Yours is anonymous and appears right away, and we don’t store who wrote it.
Or follow Regeneron Pharmaceuticals to see the first post in your watchlist.
Follow Regeneron Pharmaceuticals in a feed reader, no account needed: RSS feed